… treatment of heart failure (HF) with reduced ejection fraction for decades. According to
recent and promising studies, sacubitril/valsartan (… (HFpEF), post-myocardial infarction (post-MI), …

… We think that the possible benefits of sacubitril/valsartan use in daily practice as well as
reduction in mortality and hospitalisation cannot be ignored in HF management. …

… ) and in the post-myocardial infarction setting. Future studies … in HF treatment and is achieved
through the use of guideline-… -HeFT (Valsartan Heart Failure Trial), treatment with valsartan …

… Our aim was to improve the use and target dosing of ACE … highest prevalence of coronary
heart disease across the UK.1 … 32 mg, losartan 150 mg, valsartan 320 mg, bisoprolol 10 mg, …

… This study sought to evaluate the efficacy and safety of sacubitril/valsartan in patients
with heart failure with preserved ejection fraction (HFpEF) according to background …

… the risk of death and hospitalisation in patients with heart failure [Citation12]. Moreover, …
BKM was used to inhibit the signalling transduction. Our results depicted that BKM treatment …

… use of a two-sided alpha level of 0.05. We estimated that 592 deaths from … valsartan over
ramipril in preventing the development of incident heart failure in this post–myocardial infarction …

Full article: Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters,
and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic …

… for patients post myocardial infarction who attended a local … people living with heart disease
and heart failure continues to … that national guidelines recommend the use of ACE inhibitors (…

… of valsartan Valsartan was approved in 2002 for the treatment of … and valsartan, approved
for the treatment of heart failure … Peng, "Study on the application effect of bisoprolol combined …